To validate microvascular (MVI) and lymphovascular (LVI) invasion as prognostic factors in patients with renal cell carcinoma (RCC).
Patients and Methods
Data of patients with RCC who underwent radical or nephron-sparing surgery were prospectively collected from three academic centres. The occurrence of MVI and LVI was determined with standard staining protocols by experienced pathologists at the time of diagnosis. The association of MVI and LVI with clinicopathological data, metastatic spread, and cancer-specific survival (CSS) were evaluated with Fisher's exact tests, binary logistic regression analyses, and univariable and multivariable Cox proportional hazard regression models.
Results
MVI was present in 201 of 747 patients (26.9%) and was associated with advanced Tumour-Node-Metastasis (TNM) stages, high Fuhrman grades, and sarcomatoid features (all P < 0.001). MVI was associated with a higher rate of metastatic spread. LVI was present in 32 of 573 patients (5.5%) and was associated with advanced TNM stages, high Fuhrman grade, and sarcomatoid features (all P < 0.001).
Two-thirds of LVI-positive patients died (P < 0.001). Both LVI and MVI were significantly associated with CSS in all patients, clear cell RCC (ccRCC), and localised RCC in univariable analysis (all P < 0.001). On multivariable analysis, presence of MVI was identified as an independent prognostic factor (hazard ratio 2.09; P = 0.001). Moreover, MVI [odds ratio (OR) 2.7; P = 0.001] and not macrovascular invasion (P = 0.895) was an independent predictor of sychronuous metastatic spread. LVI was the strongest factor associated with sychronous metastatic spread (OR 4.73, 95% confidence interval 1.84-12.14; P = 0.001) in all patients and in the subgroup of patients with ccRCC (P = 0.001).
Introduction
Today, RCCs are mostly detected incidentally, as small renal masses, at a non-metastatic stage [1] . Most RCCs can be cured by surgery alone at this non-metastatic stage. However, 20-30% of non-metastatic tumours will relapse with development of local or distant metastatic disease [2, 3] . One of the most important challenges in treating patients with non-metastatic RCC is the detection of those at risk of disease recurrence in order to tailor follow-up protocols and to assign these patients to potential adjuvant treatment protocols.
Clinicopathological features that are associated with recurrence-free survival (RFS) and cancer-specific survival (CSS) have been intensively studied in recent years. For example, the American Joint Cancer Committee/Union Internationale Contre le Cancer (AJCC/UICC) TNM classification system of renal tumours is a strong prognosticator of CSS in patients with RCC [4, 5] and determines the basis of prognostication scores, e.g. the University of California at Los Angeles Integrated Staging System (UISS), which uses classical prognostic factors [TNM, Fuhrman grade, Eastern Cooperative Oncology Group performance status (ECOG PS)] to stratify patients into low-, intermediate-, and high-risk groups [6] .
In addition to providing reliable and reproducible results, current staging systems are convenient to use in the routine setting. Much effort has been expended in the discovery of genetic and molecular biomarkers to improve the accuracy of current staging systems [7] . However, neither genetic nor molecular markers can currently be recommended for reliable prognostication in RCC [1, 8] . Therefore, classic pathological features are still the most important prognostic tools in RCC.
Metastatic spread of RCC occurs via haematogenous and lymphatic routes. Macroscopic tumour invasion into the renal and caval vein has been recognised as a prognostic factor in the AJCC/UICC TNM system for a long time [4] . In contrast, microvascular invasion (MVI) is not an acknowledged risk factor of renal tumours in the 2016 revised TNM system. Recently, the International Society of Urological Pathology (ISUP) recommended that MVI should not be assessed as a prognostic factor in routine evaluation [8] . Likewise, the German S3 Guideline for Diagnosis, Therapy and Follow-up of Renal Cell Carcinoma does not advise the routine determination of MVI in RCC [9] . However, several reports have evaluated the prognostic role of MVI in RCC. Most of these reports describe the adverse prognostic role of MVI. This has recently been confirmed by a meta-analysis of retrospective cohorts [10, 11] . Similar to MVI, microscopic lymphovascular invasion (LVI) into small lymphatic vessels can be routinely assessed. It has been suggested to be an independent prognostic factor for RFS and CSS in nonmetastatic RCC [12] .
The routine evaluation of MVI (V1) and LVI (L1) in renal specimens is a widely used practice in most central European institutions, despite guideline recommendations. The importance of a clear pathway of discovery, validation, and clinical qualification of biomarkers has been acknowledged as a goal for the use of biomarkers in clinical practice by several organisations, e.g. the Biomarkers Task Force of the National Cancer Institute (NCI) Investigational Drug Steering Committee [13] . Some biomarkers can only be partly recommended for routine use because of missing validation studies and missing evidence of their utility in clinical practice. Therefore, the present study aimed to validate MVI and LVI for their use in routine clinical practice in three academic centres in Europe.
Patients and Methods

Study Cohort
The present study cohort comprised patients surgically treated for RCC with partial or radical nephrectomy from three academic tertiary centres, the Departments of Urology in Greifswald and T€ ubingen, Germany and Vienna, Austria. All patient data were prospectively collected and incorporated into institutional databases approved by local institutional review boards (Greifswald #BB081/12a; Vienna #226/2009; T€ ubingen #078/2012BO2).
Postoperative follow-up was performed based on individual risk stratification according to European Association of Urology (EAU) guideline recommendations at that time, with axial imaging of the thorax and abdomen at least every 6-12 months [1] . Our database did not gather data on distant or local recurrence, as there was no agreement in follow-up techniques and definitions of recurrence over the years in the EAU guidelines. For example, the 2008 EAU guideline did not recommend routine CT scans, whilst the actual EAU guidelines clearly recommend annual CT scans in patients with low-risk RCC. Furthermore, a clear threshold time point of what constitutes 'recurrence' in RCC is still missing. It is not clear whether a patient who develops metastases during the first 3 or 6 months after surgery really has a tumour recurrence or already had micro-metastases at the time of surgery. Collectively, we decided to include recurrence as an endpoint of the present study and instead included the association of LVI and MVI with synchronous metastatic disease.
In the case of local or distant relapse, patients were treated with either surgery for local recurrence, metastasectomy or targeted therapy. All patients had access to targeted tyrosine kinase or mammalian target of rapamycin inhibitor treatment. None of the patients was treated with adjuvant or neoadjuvant therapy.
Clinical and Pathological Data
The clinical and follow-up data were retrospectively extracted from institutional databases and included: age, gender, ECOG PS [14] , AJCC/UICC TNM 2010 classification, Fuhrman nuclear grade [15] , RCC subtypes, and sarcomatoid features. Patients with node-positive (N+) disease or distant metastasis were grouped as metastatic RCC, and patients with an absence of lymph node or distant metastasis were categorised as non-metastatic RCC. In addition, patients with pN0/pNx (cN0) and M0 disease and pT1 and pT2 RCC were grouped as localised RCC, and analysed separately compared to the group of locally advanced RCC defined as pT3 and pT4 tumours [11] .
MVI and LVI assessment is part of the routine clinical evaluation of the specimen at the time of surgery. Both are defined as an invasion of neoplastic cells or tumour emboli in microscopically visible intra-tumoral vascular or lymphatic vessels as described previously [11] . In the Vienna cohort, only MVI was routinely analysed. Evaluation of specimens follows established quality controls by experienced uropathologists (S.R., F.D., A.H., M.S.) at each institution. MVI (V1) and LVI (L1) are routinely reported within the tumour formula TNM LVRG at each institution. Patients with macrovascular invasion (V2) were staged as T3 tumours. Tumour stage T3 was included in part of the TNM staging system in the multivariable analyses. Additionally, the independent prognostic value of V2 and V1 were evaluated. In this case, T-stage was excluded from the multivariable analyses to avoid autocorrelation.
To assess clinical routine data with real-life relevance an additional immunohistochemical determination of MVI and LVI was not performed for the present study.
Statistical Analyses
Continuous variables are given as the mean AE standard deviation (SD) and categorical data are given as their absolute and relative frequency. Data were compared using the chisquared test and Fisher's test for categorical data, as appropriate. The Student's t-test was used for the comparison of continuous variables. The primary endpoint of the study was CSS, which was defined as the time from the date of surgery to cancer-specific death. Patients were censored in the case of non-RCC-related death or at the time of the last follow-up. Survival times were estimated using the KaplanMeier method and compared using the log-rank test.
Binary logistic regression analyses were performed to investigate an independent association of clinicopathological features with metastatic status (N1 and/or M1).
Independent associations with survival times were assessed with univariable and multivariable Cox proportional hazard regression models. For all multivariate regression models a backward stepwise selection with the likelihood ratio criterion (inclusion/exclusion criteria P ≤ 0.05/P ≥ 0.10) was used. The hazard ratio (HR), 95% CI, and P value for the removed variable were obtained during the removal step. All variables were investigated as continuous variables to avoid overfitting of the models.
MVI was analysed in the whole cohort, whilst LVI, in a second analysis, was only investigated in the cohorts of T€ ubingen and Greifswald because LVI had not been routinely assessed in the Vienna patients. Another subgroup analysis was performed for patients with metastatic and nonmetastatic tumours, and clear cell RCC (ccRCC) and nonccRCC.
A two-sided P < 0.05 was considered statistically significant, although this cannot be interpreted as confirmatory. All data were analysed with the Statistical Package for Social Sciences software, version 23.0 (SPSS â Inc., Chicago, IL, USA).
Results
The Table 1A .
Comparison of Clinicopathological Features in MVIand LVI-Positive vs MVI-and LVI-Negative Patients
MVI was more prevalent in ccRCC than in non-ccRCC (P < 0.001) and correlated with higher T-stages, higher Fuhrman grade, presence of sarcomatoid features, lymph node metastases, microscopic tumour necrosis, and distant metastases (all P < 0.001). Gender (P = 0.280) and ECOG PS (P = 0.076) were not statistically significantly different (Table 1A ).
In LVI-positive patients, higher T-stages, higher Fuhrman grades, sarcomatoid features, metastatic lymph nodes, and distant metastases were more often present (all P < 0.001). LVI status did not correlate with a specific RCC subtype in contrast to MVI. In addition, age (P = 0.834), gender (P = 1.00), and ECOG PS (P = 0.230) did not differ between LVI-positive and LVI-negative patients (Table 1B) .
Association of MVI and LVI with Metastatic Spread
Binary logistic regression analyses were performed to examine the independent association of clinicopathological variables and metastatic spread (N+ and/or M+). A separate analysis of non-ccRCC patients was not performed due to the few patients with tumours of non-clear cell histology (10/89).
Combined analyses of LVI and MVI showed that both MVI and LVI were independent predictive variables for synchronous metastatic spread (Table 2C, vs concomitant V1+V2, and we interestingly found that V1 was the only variable able to predict metastatic spread besides LVI (P = 0.007) (Tables 2E and 3F ).
Association of MVI and LVI with Survival Outcome
Kaplan-Meier analyses showed significantly worse CSS for patients with MVI-positive or LVI-positive tumours in the whole cohort and in the subgroup of localised tumours (all P < 0.001; Fig. 1 ). For patients with metastatic RCC, neither MVI (P = 0.314) nor LVI (P = 0.148) were significantly associated with CSS.
In univariable Cox proportional hazard regression analyses, both MVI (HR 5.38) and LVI (HR 6.29) were prognosticators of CSS (both P < 0.001, Table 3A ). In the entire cohort (HR 1.79, P = 0.025) and in the sensitivity analysis of the ccRCC subgroup (HR 1.75; P = 0.031). MVI showed an independent correlation with CSS in the multivariable model (Tables 3C,  D) . Interestingly, T-stage lost its significance as an independent prognostic marker for CSS when MVI was included in the multivariable model (Table 3B-D) .
In the combined model of MVI and LVI, only MVI was an independent predictor of CSS (HR 2.01; P = 0.001). Similarly, in the sensitivity analysis of patients with ccRCC, MVI was again an independent prognostic factor for CSS (HR 2.14; P = 0.001), whilst LVI was not an independent prognostic factor (P = 0.174; Table 3B-D). In the subgroup analyses both V1 and V1+V2 status were independent prognostic factors for the CSS (Table 3E ,F).
Discussion
Routinely assessed pathological features, such as those of the TNM system, are strong prognosticators of survival in patients with RCC. The prediction of metastatic spread and prognostication of CSS in RCC is one of the most important challenges in clinical practice for the guidance of follow-up protocol and assignment to adjuvant therapy protocols. Therefore, the present analysis was performed to further define the prognostic role of the pathological factors of MVI and LVI, as part of the TNM staging assessment in RCC [16] [17] [18] . We found an association of MVI with advanced clinicopathological features and metastatic spread in all RCC subtypes and ccRCC. Furthermore, MVI was an independent prognostic factor for metastatic spread (N+ and/or M+) and CSS in the entire study cohort and in ccRCC. In addition, MVI was still an independent prognosticator of CSS when LVI was included in the multivariable model in both all patients and those with ccRCC.
The percentage of MVI-positive tumours has always been a point of scientific discussion. A previous study by Lang et al. [19] reported an independent association of MVI with CSS in RCC. In that study, a very comprehensive approach was undertaken with additional immunohistochemical investigations in order to identify MVI. The MVI detection rate was 29% (75/255) [19] . To the contrary, the detection rate of MVI was only 5.6% when using retrospective pathological reports [8, 20] . The main limitation of these studies is that MVI was not systematically investigated in many institutions [8] . Therefore, the number of patients that finally had MVI could have been underestimated and results might have been biased in the past [8, 9] . In our present study, patients have been systematically evaluated for LVI and MVI as part of the routine assessment in each of our genitourinary pathological institutions. The percentage of patients with MVI was lower in our present cohort than in the study of Lang et al. [19] because an additional post-diagnosis immunohistochemical investigation was not performed in order to reflect real-life practice of academic and non-academic institutions. However, even with routine staining methods and a systematic investigation, the percentage of MVI-positive tumours was~27% in our present study cohort and thereby substantially higher than reported previously [8, 20] . Tumours cannot always be assigned to macroscopic or microscopic invasion. The distinction between V2 and V1 and the size of a 'small vein vessel' is not accurately defined in the literature [8] . It should be discussed if additional immunohistochemical assessments are necessary to identify MVI and LVI and to better distinguish between both in the routine setting.
RCC is a heterogeneous disease with multiple RCC subgroups that all have their own clinical characteristics [21] . Renal tumours typically demonstrate one of three metastatic patterns: to lymph nodes exclusively (N+M0), to distant organs exclusively (N0M1), or to both concomitantly (N+M1). The molecular and genetic mechanisms that underlie these different routes of spread are poorly understood. It has been suggested that different members of the hypoxia-inducible factor (HIF)/vascular endothelial growth factor (VEGF) pathway are involved in the signalling that finally result in metastatic spread either via haematogenous and/or lymphatic routes [22] . Moreover, Gerlinger et al. [23] have recently reported that metastatic spread to different organ sites is caused by different cell clones.
Therefore, our present analyses were done under the assumption that both MVI and LVI are biological processes that occur independently from each other, and thus both were entered separately in the multivariable analyses. Therefore, we sought to validate the prognostic value of LVI and MVI for CSS and the association of both features with metastatic spread in RCC. The association with metastatic spread to lymph nodes and/or distant organ sites is of particular interest because today most RCCs are diagnosed at a non-metastatic tumour stage [18] .
There are just a few variables that are consistent risk factors for the development of metastatic disease that remain incurable in almost all patients with RCC [18] . Our present study confirmed well-known predictive factors for metastatic spread such as the T-stage and Fuhrman grade. Recently, the nuclear grading system has been revised [8] . This new grading system remains to be validated in the near future. The tumours in our present study cohort were graded according to the Fuhrman classification. The Fuhrman grade was an excellent predictive factor for metastatic spread, as described in numerous studies before. Beside T-stage and the Fuhrman grade, only MVI or LVI were further predictive variables in our present investigations. In our opinion, this underscores the importance of these two variables for clinical practice, and furthermore, is a clear validation of previous findings [11] . MVI showed an independent association with metastatic spread (N+ and/or M+), but not if LVI was included as an additional co-variable in the model. Here, the LVI status had a significantly stronger association with metastatic spread when compared to MVI. This result was confirmed in a sensitivity analysis of the ccRCC subgroup.
MVI and not LVI was prognostic for CSS when both variables were analysed together without consideration of the RCC subtype and in the sub-analysis of ccRCC. Whether tumour cells invade into small lymphatic or blood vessels depends on certain tumour cell clones. Each tumour cell clone that outgrowths to develop local or distant metastasis has its own propensities [23] . The reason why cells invade into lymphatic and/or blood vessels has yet to be understood in complete detail [22] . More than half of the patients with MVI and more than two-thirds of the patients with LVI were already dead at the time of our present analysis, and LVI was the most important variable associated with metastatic spread in RCC. Therefore, our present findings indicate that tumour cells that invade into lymphatic and blood microvessels are amongst the most aggressive cell clones in RCC. This is underscored by the fact that MVI but not macrovascular involvement was found as an independent prognostic factor for prediction of metastatic spread.
The present study is limited by its retrospective nature, although data were collected prospectively. We were unable to provide a centralised pathological review of all tumour specimens, and therefore the definition between MVI and macrovascular invasion may have differed between institutions. There was no prospective definition of MVI and LVI between the institutions. However, these data reflect reallife data with the definition of V1 or V2 at different sizes at different institutions. The determination of whether an invasion is macroscopically or just microscopically visible depends on the observer, and a clear size threshold is currently not available. Therefore, it should be subject of a future study to investigate whether it could be possible to determine a threshold value between V2 and V1. However, the present study provides evidence that MVI and LVI are strong prognostic factors independent from macrovascular invasion in all RCC subtypes and ccRCC, although there is obviously a need for discussion of a clear definition of macrovascular invasion and MVI. We are unable to provide RFS analyses. However, the strong association of MVI and LVI with CSS in localised disease indicates the prognostic relevance of MVI and LVI for recurrence surveillance protocols.
In summary, the present study has validated that MVI occurs in a high percentage of RCCs. MVI and LVI can be identified in a systematic pathological slide review.
Identifying both of them in clinical practice is important because the present study has shown that LVI and MVI are amongst the most significant prognostic variables for prognostication of metastatic spread and survival outcome independent from macrovascular invasion in RCC. Thus, they could be used to tailor patients for surveillance protocols, assignment to adjuvant clinical trials, and prognostication of CSS in RCC.
